Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix vs Caspofungin/Fluconazole in Candidemia and/or Invasive Candidiasis
NCT05421858Phase 3Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of fosmanogepix in candidemia and invasive candidiasis (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Overall Survival at Day 30 and Overall Response of Treatment Success. Started Dec 2024; status: recruiting.
02
Drugs
fosmanogepix
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT05421858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421858.